Input

{
  "researchQuestion": "* How do major commercial and Medicare Advantage plans currently cover anti-obesity medications? * What utilization management strategies (e.g., prior auth, step therapy) are most commonly applied? * What clinical and economic evidence do payers prioritize when evaluating obesity therapies? * How are payers assessing long-term outcomes such as cardiovascular risk reduction and healthcare cost offsets? * What are the key concerns payers have regarding adherence, discontinuation, and real-world effectiveness? * How do employer-sponsored plans influence payer coverage decisions in obesity? * What unmet needs remain from the payer perspective in this therapeutic area? * How do current competitors position their value propositions to payers?",
  "researchGeography": "United States",
  "researchObjective": "* Assess current and evolving payer coverage policies for obesity medications * Identify key drivers of favorable vs restrictive access decisions * Understand evidence expectations for formulary inclusion and tiering * Evaluate how payers define and measure “value” in obesity treatment * Identify access barriers and opportunities for differentiation",
  "researchExtraNotes": "* Prioritize insights from national and regional commercial payers, as well as PBMs * Include recent policy updates or coverage changes within the last 12–18 months * Capture both published evidence and gray literature (e.g., payer policy documents, advisory boards, conference insights) * Highlight differences between pharmacy vs medical benefit coverage where relevant * Identify any innovative contracting models (e.g., outcomes-based agreements) emerging in this space * Where possible, include direct payer quotes or summarized perspectives to support qualitative insights",
  "researchTargetTopic": "US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies"
}

Output

{
  "output": {
    "deckOutline": {
      "Title": "Kickoff Deck Outline: US Payer Coverage, Access, and Value Assessment Trends for Anti-Obesity Pharmacotherapies",
      "1. Deck objective": "Align the team on the research scope, key questions, evidence standards, and delivery plan for understanding payer coverage and value assessment of anti-obesity medications in the US.",
      "6. Immediate next steps": [
        "Confirm in-scope products and payer segments",
        "Share source preferences and deliverable expectations",
        "Provide any existing internal materials or hypotheses",
        "Set milestone dates for draft review and final readout",
        "Assign owners for client inputs and approvals"
      ],
      "5. Risks and open questions": [
        "Coverage policies may change quickly during the research window",
        "Public documentation may not fully reflect actual payer decision-making",
        "Outcomes-based contracting may be difficult to verify if not publicly disclosed",
        "Employer-sponsored influence may be indirect and hard to isolate",
        "Medicare Advantage and commercial policies may diverge materially",
        "The scope of competitor comparison may need tightening"
      ],
      "4. Materials and inputs to request": [
        "List of in-scope anti-obesity therapies and competitors",
        "Priority payer list, including national, regional, PBM, and Medicare Advantage plans",
        "Any internal market access hypotheses or known payer concerns",
        "Prior research, slide decks, or policy trackers",
        "Target timing for recent policy change capture",
        "Any preferred source list, formatting, or citation requirements"
      ],
      "3. Recommended kickoff deck outline": [
        {
          "Purpose": "Set the reason for the research and how findings will be used.",
          "Slide title": "1. Project purpose and intended decisions",
          "Key topics to cover": [
            "Research objective and business question",
            "Primary decisions the work should inform",
            "Target audience for the final output"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm the main use case for the research",
            "Align on what success looks like for the final deliverable"
          ]
        },
        {
          "Purpose": "Define what is included and excluded to avoid scope drift.",
          "Slide title": "2. Scope of research",
          "Key topics to cover": [
            "Therapeutic area and product class boundaries",
            "US payer segments in scope",
            "Time period for recent policy review",
            "Pharmacy vs medical benefit considerations"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm product list and payer segment priorities",
            "Confirm any explicit exclusions"
          ]
        },
        {
          "Purpose": "Translate the objective into a clear question set.",
          "Slide title": "3. Core research questions",
          "Key topics to cover": [
            "Coverage and access status by payer type",
            "Utilization management approaches",
            "Evidence priorities and value criteria",
            "Views on long-term outcomes and cost offsets",
            "Access barriers and unmet needs"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Agree on the question hierarchy",
            "Identify any must-answer questions"
          ]
        },
        {
          "Purpose": "Align on what sources will count as strong evidence.",
          "Slide title": "4. Evidence and source hierarchy",
          "Key topics to cover": [
            "Published policy documents and formulary files",
            "Gray literature and conference insights",
            "Direct payer quotes and summarized perspectives",
            "Recent policy updates and change tracking"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm source preference and citation standards",
            "Confirm how to treat anecdotal vs documented evidence"
          ]
        },
        {
          "Purpose": "Clarify how the payer universe will be grouped and compared.",
          "Slide title": "5. Payer segmentation approach",
          "Key topics to cover": [
            "National commercial plans",
            "Regional commercial plans",
            "PBMs",
            "Medicare Advantage plans",
            "Employer-sponsored influence"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm segmentation logic and any priority accounts or plans",
            "Decide whether employer influence is a standalone lens or a supporting theme"
          ]
        },
        {
          "Purpose": "Show how coverage will be evaluated consistently across payers.",
          "Slide title": "6. Access and coverage assessment framework",
          "Key topics to cover": [
            "Formulary inclusion and tiering",
            "Prior authorization and step therapy",
            "Plan exclusions and restrictions",
            "Pharmacy vs medical benefit placement"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm the evaluation framework and comparison criteria",
            "Agree on how to handle mixed or ambiguous coverage policies"
          ]
        },
        {
          "Purpose": "Define what evidence payers require to support access.",
          "Slide title": "7. Value assessment and evidence expectations",
          "Key topics to cover": [
            "Clinical efficacy and safety",
            "Real-world effectiveness",
            "CV risk reduction and other long-term outcomes",
            "Healthcare cost offsets and budget impact",
            "Adherence and discontinuation concerns"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm which evidence dimensions matter most",
            "Align on how value will be interpreted across payer types"
          ]
        },
        {
          "Purpose": "Surface innovation in contracting and competitive positioning.",
          "Slide title": "8. Emerging contracting and differentiation themes",
          "Key topics to cover": [
            "Outcomes-based agreements",
            "Alternative access or contracting models",
            "Competitor value propositions to payers"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm whether contracting is a core or exploratory workstream",
            "Identify any competitors that must be included"
          ]
        },
        {
          "Purpose": "Set expectations for sequencing, milestones, and review points.",
          "Slide title": "9. Workplan and timeline",
          "Key topics to cover": [
            "Research phases",
            "Internal check-ins and readouts",
            "Draft and final deliverables",
            "Dependencies and timing"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm timeline and milestone dates",
            "Agree on review cadence and approval process"
          ]
        },
        {
          "Purpose": "Specify what the client must provide to enable the work.",
          "Slide title": "10. Client inputs needed",
          "Key topics to cover": [
            "Priority products and competitors",
            "Target payer list or account priorities",
            "Any prior research or internal perspectives",
            "Access to internal claims or market access materials if relevant"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Assign owners for each input",
            "Set deadlines for delivery"
          ]
        },
        {
          "Purpose": "Surface issues that could affect quality, timing, or interpretability.",
          "Slide title": "11. Risks, dependencies, and open questions",
          "Key topics to cover": [
            "Rapidly changing coverage landscape",
            "Incomplete or inconsistent payer documentation",
            "Limited transparency around contracting",
            "Differences between commercial and Medicare Advantage decisions"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm how to manage gaps in public data",
            "Decide escalation path for unresolved questions"
          ]
        },
        {
          "Purpose": "Close kickoff with clear actions and ownership.",
          "Slide title": "12. Immediate next steps",
          "Key topics to cover": [
            "Finalize scope and payer list",
            "Share input materials",
            "Begin evidence collection and policy review",
            "Schedule first working session"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm owners and due dates",
            "Approve next meeting and first checkpoint"
          ]
        }
      ],
      "2. What we know / assumptions / gaps": {
        "Assumptions": [
          "The project is a secondary research / market access intelligence effort rather than primary qualitative research only",
          "Coverage differences by pharmacy vs medical benefit will be relevant for at least some products and plans",
          "Outcomes-based contracting may be present but likely limited and should be assessed as an emerging theme"
        ],
        "Known facts": [
          "Topic: US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies",
          "Geography: United States",
          "Priority stakeholders: national and regional commercial payers, PBMs, and Medicare Advantage plans",
          "Focus areas: coverage policies, utilization management, evidence expectations, value definitions, long-term outcomes, adherence/discontinuation, employer influence, competitor positioning",
          "Need to incorporate recent policy changes from the last 12–18 months",
          "Need to include published evidence plus gray literature and payer quotes where available"
        ],
        "Gaps to confirm": [
          "Which specific anti-obesity therapies are in scope",
          "Whether the output should prioritize payer-policy mapping, narrative insights, or both",
          "Depth expected for Medicare Advantage vs commercial vs employer-sponsored plans",
          "Expected level of citation detail and source hierarchy",
          "Deliverable timeline and whether interim readouts are needed"
        ]
      }
    }
  }
}

Runtime context

{
  "memoryMode": "RUN_SCOPED",
  "stepOutputs": [
    {
      "output": {
        "deckOutline": {
          "Title": "Kickoff Deck Outline: US Payer Coverage, Access, and Value Assessment Trends for Anti-Obesity Pharmacotherapies",
          "1. Deck objective": "Align the team on the research scope, key questions, evidence standards, and delivery plan for understanding payer coverage and value assessment of anti-obesity medications in the US.",
          "6. Immediate next steps": [
            "Confirm in-scope products and payer segments",
            "Share source preferences and deliverable expectations",
            "Provide any existing internal materials or hypotheses",
            "Set milestone dates for draft review and final readout",
            "Assign owners for client inputs and approvals"
          ],
          "5. Risks and open questions": [
            "Coverage policies may change quickly during the research window",
            "Public documentation may not fully reflect actual payer decision-making",
            "Outcomes-based contracting may be difficult to verify if not publicly disclosed",
            "Employer-sponsored influence may be indirect and hard to isolate",
            "Medicare Advantage and commercial policies may diverge materially",
            "The scope of competitor comparison may need tightening"
          ],
          "4. Materials and inputs to request": [
            "List of in-scope anti-obesity therapies and competitors",
            "Priority payer list, including national, regional, PBM, and Medicare Advantage plans",
            "Any internal market access hypotheses or known payer concerns",
            "Prior research, slide decks, or policy trackers",
            "Target timing for recent policy change capture",
            "Any preferred source list, formatting, or citation requirements"
          ],
          "3. Recommended kickoff deck outline": [
            {
              "Purpose": "Set the reason for the research and how findings will be used.",
              "Slide title": "1. Project purpose and intended decisions",
              "Key topics to cover": [
                "Research objective and business question",
                "Primary decisions the work should inform",
                "Target audience for the final output"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm the main use case for the research",
                "Align on what success looks like for the final deliverable"
              ]
            },
            {
              "Purpose": "Define what is included and excluded to avoid scope drift.",
              "Slide title": "2. Scope of research",
              "Key topics to cover": [
                "Therapeutic area and product class boundaries",
                "US payer segments in scope",
                "Time period for recent policy review",
                "Pharmacy vs medical benefit considerations"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm product list and payer segment priorities",
                "Confirm any explicit exclusions"
              ]
            },
            {
              "Purpose": "Translate the objective into a clear question set.",
              "Slide title": "3. Core research questions",
              "Key topics to cover": [
                "Coverage and access status by payer type",
                "Utilization management approaches",
                "Evidence priorities and value criteria",
                "Views on long-term outcomes and cost offsets",
                "Access barriers and unmet needs"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Agree on the question hierarchy",
                "Identify any must-answer questions"
              ]
            },
            {
              "Purpose": "Align on what sources will count as strong evidence.",
              "Slide title": "4. Evidence and source hierarchy",
              "Key topics to cover": [
                "Published policy documents and formulary files",
                "Gray literature and conference insights",
                "Direct payer quotes and summarized perspectives",
                "Recent policy updates and change tracking"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm source preference and citation standards",
                "Confirm how to treat anecdotal vs documented evidence"
              ]
            },
            {
              "Purpose": "Clarify how the payer universe will be grouped and compared.",
              "Slide title": "5. Payer segmentation approach",
              "Key topics to cover": [
                "National commercial plans",
                "Regional commercial plans",
                "PBMs",
                "Medicare Advantage plans",
                "Employer-sponsored influence"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm segmentation logic and any priority accounts or plans",
                "Decide whether employer influence is a standalone lens or a supporting theme"
              ]
            },
            {
              "Purpose": "Show how coverage will be evaluated consistently across payers.",
              "Slide title": "6. Access and coverage assessment framework",
              "Key topics to cover": [
                "Formulary inclusion and tiering",
                "Prior authorization and step therapy",
                "Plan exclusions and restrictions",
                "Pharmacy vs medical benefit placement"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm the evaluation framework and comparison criteria",
                "Agree on how to handle mixed or ambiguous coverage policies"
              ]
            },
            {
              "Purpose": "Define what evidence payers require to support access.",
              "Slide title": "7. Value assessment and evidence expectations",
              "Key topics to cover": [
                "Clinical efficacy and safety",
                "Real-world effectiveness",
                "CV risk reduction and other long-term outcomes",
                "Healthcare cost offsets and budget impact",
                "Adherence and discontinuation concerns"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm which evidence dimensions matter most",
                "Align on how value will be interpreted across payer types"
              ]
            },
            {
              "Purpose": "Surface innovation in contracting and competitive positioning.",
              "Slide title": "8. Emerging contracting and differentiation themes",
              "Key topics to cover": [
                "Outcomes-based agreements",
                "Alternative access or contracting models",
                "Competitor value propositions to payers"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm whether contracting is a core or exploratory workstream",
                "Identify any competitors that must be included"
              ]
            },
            {
              "Purpose": "Set expectations for sequencing, milestones, and review points.",
              "Slide title": "9. Workplan and timeline",
              "Key topics to cover": [
                "Research phases",
                "Internal check-ins and readouts",
                "Draft and final deliverables",
                "Dependencies and timing"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm timeline and milestone dates",
                "Agree on review cadence and approval process"
              ]
            },
            {
              "Purpose": "Specify what the client must provide to enable the work.",
              "Slide title": "10. Client inputs needed",
              "Key topics to cover": [
                "Priority products and competitors",
                "Target payer list or account priorities",
                "Any prior research or internal perspectives",
                "Access to internal claims or market access materials if relevant"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Assign owners for each input",
                "Set deadlines for delivery"
              ]
            },
            {
              "Purpose": "Surface issues that could affect quality, timing, or interpretability.",
              "Slide title": "11. Risks, dependencies, and open questions",
              "Key topics to cover": [
                "Rapidly changing coverage landscape",
                "Incomplete or inconsistent payer documentation",
                "Limited transparency around contracting",
                "Differences between commercial and Medicare Advantage decisions"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm how to manage gaps in public data",
                "Decide escalation path for unresolved questions"
              ]
            },
            {
              "Purpose": "Close kickoff with clear actions and ownership.",
              "Slide title": "12. Immediate next steps",
              "Key topics to cover": [
                "Finalize scope and payer list",
                "Share input materials",
                "Begin evidence collection and policy review",
                "Schedule first working session"
              ],
              "Critical decisions, questions, or confirmations tied to the slide": [
                "Confirm owners and due dates",
                "Approve next meeting and first checkpoint"
              ]
            }
          ],
          "2. What we know / assumptions / gaps": {
            "Assumptions": [
              "The project is a secondary research / market access intelligence effort rather than primary qualitative research only",
              "Coverage differences by pharmacy vs medical benefit will be relevant for at least some products and plans",
              "Outcomes-based contracting may be present but likely limited and should be assessed as an emerging theme"
            ],
            "Known facts": [
              "Topic: US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies",
              "Geography: United States",
              "Priority stakeholders: national and regional commercial payers, PBMs, and Medicare Advantage plans",
              "Focus areas: coverage policies, utilization management, evidence expectations, value definitions, long-term outcomes, adherence/discontinuation, employer influence, competitor positioning",
              "Need to incorporate recent policy changes from the last 12–18 months",
              "Need to include published evidence plus gray literature and payer quotes where available"
            ],
            "Gaps to confirm": [
              "Which specific anti-obesity therapies are in scope",
              "Whether the output should prioritize payer-policy mapping, narrative insights, or both",
              "Depth expected for Medicare Advantage vs commercial vs employer-sponsored plans",
              "Expected level of citation detail and source hierarchy",
              "Deliverable timeline and whether interim readouts are needed"
            ]
          }
        }
      },
      "status": "SUCCEEDED",
      "stepKey": "kickoff-deck-generate",
      "telemetry": {
        "cost": {
          "model": "gpt-5.4-mini",
          "actualUsd": 0.008089,
          "estimatedUsd": null,
          "pricingSource": "openai-api-pricing-2026-04-28-standard"
        },
        "usage": {
          "inputTokens": 1557,
          "totalTokens": 3095,
          "input_tokens": 1557,
          "outputTokens": 1538,
          "total_tokens": 3095,
          "output_tokens": 1538
        },
        "status": "SUCCEEDED",
        "provider": "OPENAI",
        "durationMs": 12404,
        "providerMode": "agents-sdk",
        "excludedToolKeys": [],
        "rawResponseCount": 1,
        "outputSchemaEnabled": true
      }
    }
  ]
}

Telemetry

{
  "cost": {
    "actualUsd": 0.008089,
    "estimatedUsd": null,
    "pricingSource": "openai-api-pricing-2026-04-28-standard"
  },
  "usage": {
    "inputTokens": 1557,
    "totalTokens": 3095,
    "outputTokens": 1538
  },
  "status": "SUCCEEDED",
  "provider": "OPENAI",
  "stepCount": 1,
  "durationMs": 12475,
  "alertableEvents": [],
  "failedStepCount": 0,
  "completedStepCount": 1
}

Step runs

{
  "output": {
    "deckOutline": {
      "Title": "Kickoff Deck Outline: US Payer Coverage, Access, and Value Assessment Trends for Anti-Obesity Pharmacotherapies",
      "1. Deck objective": "Align the team on the research scope, key questions, evidence standards, and delivery plan for understanding payer coverage and value assessment of anti-obesity medications in the US.",
      "6. Immediate next steps": [
        "Confirm in-scope products and payer segments",
        "Share source preferences and deliverable expectations",
        "Provide any existing internal materials or hypotheses",
        "Set milestone dates for draft review and final readout",
        "Assign owners for client inputs and approvals"
      ],
      "5. Risks and open questions": [
        "Coverage policies may change quickly during the research window",
        "Public documentation may not fully reflect actual payer decision-making",
        "Outcomes-based contracting may be difficult to verify if not publicly disclosed",
        "Employer-sponsored influence may be indirect and hard to isolate",
        "Medicare Advantage and commercial policies may diverge materially",
        "The scope of competitor comparison may need tightening"
      ],
      "4. Materials and inputs to request": [
        "List of in-scope anti-obesity therapies and competitors",
        "Priority payer list, including national, regional, PBM, and Medicare Advantage plans",
        "Any internal market access hypotheses or known payer concerns",
        "Prior research, slide decks, or policy trackers",
        "Target timing for recent policy change capture",
        "Any preferred source list, formatting, or citation requirements"
      ],
      "3. Recommended kickoff deck outline": [
        {
          "Purpose": "Set the reason for the research and how findings will be used.",
          "Slide title": "1. Project purpose and intended decisions",
          "Key topics to cover": [
            "Research objective and business question",
            "Primary decisions the work should inform",
            "Target audience for the final output"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm the main use case for the research",
            "Align on what success looks like for the final deliverable"
          ]
        },
        {
          "Purpose": "Define what is included and excluded to avoid scope drift.",
          "Slide title": "2. Scope of research",
          "Key topics to cover": [
            "Therapeutic area and product class boundaries",
            "US payer segments in scope",
            "Time period for recent policy review",
            "Pharmacy vs medical benefit considerations"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm product list and payer segment priorities",
            "Confirm any explicit exclusions"
          ]
        },
        {
          "Purpose": "Translate the objective into a clear question set.",
          "Slide title": "3. Core research questions",
          "Key topics to cover": [
            "Coverage and access status by payer type",
            "Utilization management approaches",
            "Evidence priorities and value criteria",
            "Views on long-term outcomes and cost offsets",
            "Access barriers and unmet needs"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Agree on the question hierarchy",
            "Identify any must-answer questions"
          ]
        },
        {
          "Purpose": "Align on what sources will count as strong evidence.",
          "Slide title": "4. Evidence and source hierarchy",
          "Key topics to cover": [
            "Published policy documents and formulary files",
            "Gray literature and conference insights",
            "Direct payer quotes and summarized perspectives",
            "Recent policy updates and change tracking"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm source preference and citation standards",
            "Confirm how to treat anecdotal vs documented evidence"
          ]
        },
        {
          "Purpose": "Clarify how the payer universe will be grouped and compared.",
          "Slide title": "5. Payer segmentation approach",
          "Key topics to cover": [
            "National commercial plans",
            "Regional commercial plans",
            "PBMs",
            "Medicare Advantage plans",
            "Employer-sponsored influence"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm segmentation logic and any priority accounts or plans",
            "Decide whether employer influence is a standalone lens or a supporting theme"
          ]
        },
        {
          "Purpose": "Show how coverage will be evaluated consistently across payers.",
          "Slide title": "6. Access and coverage assessment framework",
          "Key topics to cover": [
            "Formulary inclusion and tiering",
            "Prior authorization and step therapy",
            "Plan exclusions and restrictions",
            "Pharmacy vs medical benefit placement"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm the evaluation framework and comparison criteria",
            "Agree on how to handle mixed or ambiguous coverage policies"
          ]
        },
        {
          "Purpose": "Define what evidence payers require to support access.",
          "Slide title": "7. Value assessment and evidence expectations",
          "Key topics to cover": [
            "Clinical efficacy and safety",
            "Real-world effectiveness",
            "CV risk reduction and other long-term outcomes",
            "Healthcare cost offsets and budget impact",
            "Adherence and discontinuation concerns"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm which evidence dimensions matter most",
            "Align on how value will be interpreted across payer types"
          ]
        },
        {
          "Purpose": "Surface innovation in contracting and competitive positioning.",
          "Slide title": "8. Emerging contracting and differentiation themes",
          "Key topics to cover": [
            "Outcomes-based agreements",
            "Alternative access or contracting models",
            "Competitor value propositions to payers"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm whether contracting is a core or exploratory workstream",
            "Identify any competitors that must be included"
          ]
        },
        {
          "Purpose": "Set expectations for sequencing, milestones, and review points.",
          "Slide title": "9. Workplan and timeline",
          "Key topics to cover": [
            "Research phases",
            "Internal check-ins and readouts",
            "Draft and final deliverables",
            "Dependencies and timing"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm timeline and milestone dates",
            "Agree on review cadence and approval process"
          ]
        },
        {
          "Purpose": "Specify what the client must provide to enable the work.",
          "Slide title": "10. Client inputs needed",
          "Key topics to cover": [
            "Priority products and competitors",
            "Target payer list or account priorities",
            "Any prior research or internal perspectives",
            "Access to internal claims or market access materials if relevant"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Assign owners for each input",
            "Set deadlines for delivery"
          ]
        },
        {
          "Purpose": "Surface issues that could affect quality, timing, or interpretability.",
          "Slide title": "11. Risks, dependencies, and open questions",
          "Key topics to cover": [
            "Rapidly changing coverage landscape",
            "Incomplete or inconsistent payer documentation",
            "Limited transparency around contracting",
            "Differences between commercial and Medicare Advantage decisions"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm how to manage gaps in public data",
            "Decide escalation path for unresolved questions"
          ]
        },
        {
          "Purpose": "Close kickoff with clear actions and ownership.",
          "Slide title": "12. Immediate next steps",
          "Key topics to cover": [
            "Finalize scope and payer list",
            "Share input materials",
            "Begin evidence collection and policy review",
            "Schedule first working session"
          ],
          "Critical decisions, questions, or confirmations tied to the slide": [
            "Confirm owners and due dates",
            "Approve next meeting and first checkpoint"
          ]
        }
      ],
      "2. What we know / assumptions / gaps": {
        "Assumptions": [
          "The project is a secondary research / market access intelligence effort rather than primary qualitative research only",
          "Coverage differences by pharmacy vs medical benefit will be relevant for at least some products and plans",
          "Outcomes-based contracting may be present but likely limited and should be assessed as an emerging theme"
        ],
        "Known facts": [
          "Topic: US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies",
          "Geography: United States",
          "Priority stakeholders: national and regional commercial payers, PBMs, and Medicare Advantage plans",
          "Focus areas: coverage policies, utilization management, evidence expectations, value definitions, long-term outcomes, adherence/discontinuation, employer influence, competitor positioning",
          "Need to incorporate recent policy changes from the last 12–18 months",
          "Need to include published evidence plus gray literature and payer quotes where available"
        ],
        "Gaps to confirm": [
          "Which specific anti-obesity therapies are in scope",
          "Whether the output should prioritize payer-policy mapping, narrative insights, or both",
          "Depth expected for Medicare Advantage vs commercial vs employer-sponsored plans",
          "Expected level of citation detail and source hierarchy",
          "Deliverable timeline and whether interim readouts are needed"
        ]
      }
    }
  },
  "status": "completed",
  "rawProviderText": "{\"deckOutline\":{\"Title\":\"Kickoff Deck Outline: US Payer Coverage, Access, and Value Assessment Trends for Anti-Obesity Pharmacotherapies\",\"1. Deck objective\":\"Align the team on the research scope, key questions, evidence standards, and delivery plan for understanding payer coverage and value assessment of anti-obesity medications in the US.\",\"2. What we know / assumptions / gaps\":{\"Known facts\":[\"Topic: US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies\",\"Geography: United States\",\"Priority stakeholders: national and regional commercial payers, PBMs, and Medicare Advantage plans\",\"Focus areas: coverage policies, utilization management, evidence expectations, value definitions, long-term outcomes, adherence/discontinuation, employer influence, competitor positioning\",\"Need to incorporate recent policy changes from the last 12–18 months\",\"Need to include published evidence plus gray literature and payer quotes where available\"],\"Assumptions\":[\"The project is a secondary research / market access intelligence effort rather than primary qualitative research only\",\"Coverage differences by pharmacy vs medical benefit will be relevant for at least some products and plans\",\"Outcomes-based contracting may be present but likely limited and should be assessed as an emerging theme\"],\"Gaps to confirm\":[\"Which specific anti-obesity therapies are in scope\",\"Whether the output should prioritize payer-policy mapping, narrative insights, or both\",\"Depth expected for Medicare Advantage vs commercial vs employer-sponsored plans\",\"Expected level of citation detail and source hierarchy\",\"Deliverable timeline and whether interim readouts are needed\"]},\"3. Recommended kickoff deck outline\":[{\"Slide title\":\"1. Project purpose and intended decisions\",\"Purpose\":\"Set the reason for the research and how findings will be used.\",\"Key topics to cover\":[\"Research objective and business question\",\"Primary decisions the work should inform\",\"Target audience for the final output\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm the main use case for the research\",\"Align on what success looks like for the final deliverable\"]},{\"Slide title\":\"2. Scope of research\",\"Purpose\":\"Define what is included and excluded to avoid scope drift.\",\"Key topics to cover\":[\"Therapeutic area and product class boundaries\",\"US payer segments in scope\",\"Time period for recent policy review\",\"Pharmacy vs medical benefit considerations\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm product list and payer segment priorities\",\"Confirm any explicit exclusions\"]},{\"Slide title\":\"3. Core research questions\",\"Purpose\":\"Translate the objective into a clear question set.\",\"Key topics to cover\":[\"Coverage and access status by payer type\",\"Utilization management approaches\",\"Evidence priorities and value criteria\",\"Views on long-term outcomes and cost offsets\",\"Access barriers and unmet needs\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Agree on the question hierarchy\",\"Identify any must-answer questions\"]},{\"Slide title\":\"4. Evidence and source hierarchy\",\"Purpose\":\"Align on what sources will count as strong evidence.\",\"Key topics to cover\":[\"Published policy documents and formulary files\",\"Gray literature and conference insights\",\"Direct payer quotes and summarized perspectives\",\"Recent policy updates and change tracking\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm source preference and citation standards\",\"Confirm how to treat anecdotal vs documented evidence\"]},{\"Slide title\":\"5. Payer segmentation approach\",\"Purpose\":\"Clarify how the payer universe will be grouped and compared.\",\"Key topics to cover\":[\"National commercial plans\",\"Regional commercial plans\",\"PBMs\",\"Medicare Advantage plans\",\"Employer-sponsored influence\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm segmentation logic and any priority accounts or plans\",\"Decide whether employer influence is a standalone lens or a supporting theme\"]},{\"Slide title\":\"6. Access and coverage assessment framework\",\"Purpose\":\"Show how coverage will be evaluated consistently across payers.\",\"Key topics to cover\":[\"Formulary inclusion and tiering\",\"Prior authorization and step therapy\",\"Plan exclusions and restrictions\",\"Pharmacy vs medical benefit placement\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm the evaluation framework and comparison criteria\",\"Agree on how to handle mixed or ambiguous coverage policies\"]},{\"Slide title\":\"7. Value assessment and evidence expectations\",\"Purpose\":\"Define what evidence payers require to support access.\",\"Key topics to cover\":[\"Clinical efficacy and safety\",\"Real-world effectiveness\",\"CV risk reduction and other long-term outcomes\",\"Healthcare cost offsets and budget impact\",\"Adherence and discontinuation concerns\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm which evidence dimensions matter most\",\"Align on how value will be interpreted across payer types\"]},{\"Slide title\":\"8. Emerging contracting and differentiation themes\",\"Purpose\":\"Surface innovation in contracting and competitive positioning.\",\"Key topics to cover\":[\"Outcomes-based agreements\",\"Alternative access or contracting models\",\"Competitor value propositions to payers\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm whether contracting is a core or exploratory workstream\",\"Identify any competitors that must be included\"]},{\"Slide title\":\"9. Workplan and timeline\",\"Purpose\":\"Set expectations for sequencing, milestones, and review points.\",\"Key topics to cover\":[\"Research phases\",\"Internal check-ins and readouts\",\"Draft and final deliverables\",\"Dependencies and timing\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm timeline and milestone dates\",\"Agree on review cadence and approval process\"]},{\"Slide title\":\"10. Client inputs needed\",\"Purpose\":\"Specify what the client must provide to enable the work.\",\"Key topics to cover\":[\"Priority products and competitors\",\"Target payer list or account priorities\",\"Any prior research or internal perspectives\",\"Access to internal claims or market access materials if relevant\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Assign owners for each input\",\"Set deadlines for delivery\"]},{\"Slide title\":\"11. Risks, dependencies, and open questions\",\"Purpose\":\"Surface issues that could affect quality, timing, or interpretability.\",\"Key topics to cover\":[\"Rapidly changing coverage landscape\",\"Incomplete or inconsistent payer documentation\",\"Limited transparency around contracting\",\"Differences between commercial and Medicare Advantage decisions\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm how to manage gaps in public data\",\"Decide escalation path for unresolved questions\"]},{\"Slide title\":\"12. Immediate next steps\",\"Purpose\":\"Close kickoff with clear actions and ownership.\",\"Key topics to cover\":[\"Finalize scope and payer list\",\"Share input materials\",\"Begin evidence collection and policy review\",\"Schedule first working session\"],\"Critical decisions, questions, or confirmations tied to the slide\":[\"Confirm owners and due dates\",\"Approve next meeting and first checkpoint\"]}],\"4. Materials and inputs to request\":[\"List of in-scope anti-obesity therapies and competitors\",\"Priority payer list, including national, regional, PBM, and Medicare Advantage plans\",\"Any internal market access hypotheses or known payer concerns\",\"Prior research, slide decks, or policy trackers\",\"Target timing for recent policy change capture\",\"Any preferred source list, formatting, or citation requirements\"],\"5. Risks and open questions\":[\"Coverage policies may change quickly during the research window\",\"Public documentation may not fully reflect actual payer decision-making\",\"Outcomes-based contracting may be difficult to verify if not publicly disclosed\",\"Employer-sponsored influence may be indirect and hard to isolate\",\"Medicare Advantage and commercial policies may diverge materially\",\"The scope of competitor comparison may need tightening\"],\"6. Immediate next steps\":[\"Confirm in-scope products and payer segments\",\"Share source preferences and deliverable expectations\",\"Provide any existing internal materials or hypotheses\",\"Set milestone dates for draft review and final readout\",\"Assign owners for client inputs and approvals\"]}}",
  "providerResponseId": "resp_0658c86eebac13ba006a05f3d13488819198e690a0b28a99a5"
}